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In 2012, there were 140,000 new cases of gastric cancer
diagnosed across all European countries, making it the sixth com-
monest cancer diagnosis. Perhaps more importantly, it remains
the fourth commonest cause of cancer-related death, being
responsible for 107,000 deaths annually [1]. Despite a gradual
decline in the worldwide incidence of gastric cancers, there has
been a relative increase in the incidence of tumours of the oeso-
phago–gastric junction (OGJ) and gastric cardia. The peak inci-
dence is in the 7th decade, and the disease is approximately
twice as common in men as in women. There is marked
geographic variation, with the highest rates in East Asia, South
America and Eastern Europe and the lowest rates in the United
States and Western Europe [2].The risk factors for gastric cancer include male gender, cigarette
smoking, Helicobacter pylori infection, atrophic gastritis, partial
gastrectomy, and Ménétrier’s disease. A small number of patients
may have a genetic predisposition syndrome including hereditary
non-polyposis colorectal cancer, familial adenomatous polyposis,
hereditary diffuse gastric cancer and Peutz Jeghers syndrome. If
this is suspected based upon family history then patients should
be referred to a genetics specialist for assessment as per Interna-
tional Gastric Cancer Linkage Consortium guidelines [3] [V, B].
Diagnosis and pathology
Screening for gastric cancer is routine in Japan and Korea where
the incidence is much higher than in Western countries. In symp-
tomatic patients, the presenting features commonly include
weight loss, dysphagia, dyspepsia, vomiting, early satiety, and/or
iron-deﬁciency anaemia.
Diagnosis should be made from a gastroscopic or surgical
biopsy reviewed by an experienced pathologist, and histology
should be reported according to the World Health Organisation
criteria [IV, C].
Table 1
Diagnostic and staging investigations in gastric cancer.
Procedure Purpose
Routine blood tests Check for evidence of iron-deﬁciency anaemia
Check hepatic and renal function to determine appropriate therapeutic options
Endoscopy + biopsy Obtain tissue for diagnosis, histological classiﬁcation and molecular biomarkers e.g., HER-2 status
CT thorax + abdomen ± pelvis Staging of tumour – particularly to detect local/distant lymphadenopathy and metastatic disease sites
Endoscopic ultrasound (EUS) Accurate assessment of T and N stage in potentially operable tumours
Determine proximal and distal extent of the tumour
Laparoscopy + washings To exclude occult metastatic disease involving the diaphragm/peritoneum
Positron emission tomography (PET, if available) May improve detection of occult metastatic disease in some cases
190 Clinical practice guidelinesNinety percent of gastric cancers are adenocarcinomas, and
these are sub-divided according to histological appearances
into diffuse (undifferentiated) and intestinal (well differentiated)
types (Lauren classiﬁcation). These Clinical Practice Guidelines
do not apply to rarer gastric malignancies such as gastroin-
testinal stromal tumours (GIST), lymphomas and neuro-endocrine
tumours.
Staging and risk assessment
Initial investigations include physical examination, blood count
and differential, liver and renal function tests, endoscopy and con-
trast-enhanced computed tomography (CT) scan of the thorax,
abdomen ± pelvis. Positron emission tomography (PET) imaging,
if available, may improve staging through increased detection of
involved lymph nodes/metastatic disease. However, it may be
uninformative in some patients, especially those with mucinous
tumours [III, B] (Table 1).
Endoscopic ultrasound (EUS) is helpful in determining the prox-
imal and distal extent of the tumour and provides further assess-
ment of the T and N stages, although it is less useful in antral
tumours [III, B]. Laparoscopy ± peritoneal washings for malignant
cells is recommended in all stage IB-III stomach cancers considered
to be potentially resectable to exclude occult metastatic disease
[4,5] [III, B].
The TNM classiﬁcation should be recorded and the corre-
sponding stage determined according to the 7th edition of the
Union for International Cancer Control (UICC) [6]/American Joint
Cancer Committee (AJCC) [7] guidelines and staging manual
(Tables 2 and 3). A careful tumour staging is fundamental toTable 2
TNM staging of gastric cancer (7th Edition of AJCC/UICC guidelines) [6,7].
Primary tumour (T)
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ: intraepithelial tumour without invasion of the lamina
propria
T1a Tumour invades lamina propria or muscularis mucosae
T1b Tumour invades submucosa
T2 Tumour invades muscularis propria
T3 Tumour penetrates subserosal connective tissue without invasion of visceral
peritoneum or adjacent structures*
T4a Tumour invades serosa (visceral peritoneum)
T4b Tumour invades adjacent structures**
Edge SB, Byrd DR, Compton CC, eds. AJCC Cancer Staging Handbook, 7th ed. New York,
Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer St
Media LLC, www.springer.com.
* T3 tumours also include those extending into the gastrocolic or gastrohepatic ligam
peritoneum covering these structures.
** Adjacent structures include the spleen, transverse colon, liver, diaphragm, pancreas,ensuring that patients are appropriately selected for treatment
interventions.Treatment planning
Multi-disciplinary treatment planning is mandatory. The core
membership of the multi-disciplinary team should include sur-
geons, medical and radiation oncologists, gastroenterologists, radi-
ologists, pathologists, dieticians and nurse specialists if available
[IV, C].
Management of local/locoregional disease
Surgery
Surgical resection is the only treatment modality that is poten-
tially curative, though the majority of patients still relapse follow-
ing resection and therefore combined modality approaches are
standard for >stage 1B disease. The extent of resection is deter-
mined by the pre-operative stage. Early gastric cancers (T1a) may
be amenable to endoscopic resection if they are well-differenti-
ated, <2 cm, conﬁned to the mucosa and not ulcerated [8] [III, B].
The associated lymph node metastatic risk is virtually zero for this
group. Guidelines from the National Cancer Centre in Tokyo have
expanded these criteria in patients with intestinal-type histology
and no evidence of lympho-vascular invasion to include: intramu-
cosal cancers without ulceration regardless of tumour size;
intra-mucosal cancers <3 cm with ulceration; or cancers with early
invasion into the sub-mucosa (sm1) measuring <3 cm. In this ex-
panded group the risk of lymph node metastases also remainsRegional lymph nodes (N) Distant metastasis (M)
NX Regional lymph node(s) cannot
be assessed
MX Distant metastasis cannot be
assessed
N0 No regional lymph node
metastasis
M0 No distant metastasis
N1 Metastasis in 1–2 regional
lymph nodes
M1 Distant metastasis or positive
peritoneal cytology
N2 Metastasis in 3–6 regional
lymph nodes
N3 Metastasis in 7 or more
regional lymph nodes
NY: Springer, 2010. Used with the permission of the American Joint Committee on
aging Handbook, Seventh Edition (2010) published by Springer Science and Business
ents, or into the greater or lesser omentum, without perforation of the visceral
abdominal wall, adrenal gland, kidney, small intestine and retro-peritoneum.
Table 3
AJCC/UICC stage grouping (7th edition) [6,7].
Stage Grouping T-stage N-stage M-stage
Stage 0 Tis N0 M0
Stage IA T1 N0 M0
Stage IB T1 N1 M0
T2 N0 M0
Stage IIA T1 N2 M0
T2 N1 M0
T3 N0 M0




Stage IIIA T2 N3 M0
T3 N2 M0
T4a N1 M0
Stage IIIB T3 N3 M0
T4a N2 M0
T4b N0–1 M1
Stage IIIC T4a N3 M0
T4b N2–3 M0
Stage IV Any T Any N M1
Edge SB, Byrd DR, Compton CC, eds. AJCC Cancer Staging Handbook, 7th ed. New
York, NY: Springer, 2010. Used with the permission of the American Joint Com-
mittee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the
AJCC Cancer Staging Handbook, Seventh Edition (2010) published by Springer
Science and Business Media LLC, www.springer.com.
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undertaken to permit precise histological assessment [9] [III, B].
T1 tumours which do not meet the criteria for endoscopic ther-
apy will require surgery, though the extent is less than for other
gastric cancers (see below). In particular, the lymph node dissec-
tion can be limited to peri-gastric nodes and includes local N2
nodes, referred to as D1 alpha and D1 beta according to position
of primary tumour. Sentinel node mapping may further modify
these approaches.
Radical gastrectomy is indicated for resectable stage IB-III dis-
ease. Sub-total gastrectomy may be carried out if a macroscopic
proximal margin of 5 cm can be achieved between the tumour
and the OGJ. A margin of 8 cm has been advocated for diffuse type
cancers. Otherwise a total gastrectomy is indicated [III, A]. Peri-
operative therapies should be considered in these patients (see
below).
The extent of nodal dissection accompanying radical gastrec-
tomy has been extensively debated (D1: removal of perigastric
lymph nodes versus D2: removal of perigastric lymph nodes plus
those along the left gastric, common hepatic and splenic arteries
and coeliac axis). The current UICC/AJCC TNM classiﬁcation recom-
mendations (7th edition) include excision of a minimum of 15
lymph nodes to allow reliable staging [6,7]. Experience from both
observational and randomised trials in Asian countries has demon-
strated that D2 dissection leads to superior outcomes compared to
D1 [II, B]. In the West, a Dutch [10] and a UK Medical Research
Council (MRC) trial [11] failed to demonstrate any initial survival
advantage with D2 resection. However the 15-year follow-up re-
sults from the Dutch trial [12] demonstrated fewer locoregional
recurrences and gastric cancer-related deaths with D2 resection,
though this was slightly offset by an increase in postoperative mor-
tality and morbidity. A recent meta-analysis of 12 randomised,
controlled trials (RCTs) conﬁrmed no overall survival (OS) beneﬁt
for D2 lymphadenectomy, although a beneﬁt was seen amongst
patients who had resection without splenectomy and/or pancrea-
tectomy [13]. The current consensus view in the West is that, for
patients deemed medically ﬁt, D2 dissection should be the stan-
dard procedure carried out in specialised, high-volume centres
with appropriate surgical expertise and postoperative care [14]
[I, B].Laparoscopic surgery has been evaluated as an alternative to
open surgery with the potential beneﬁts of decreased operative
morbidity and reduced recovery times. Meta-analyses conﬁrm
these beneﬁts in distal gastrectomy, though some concerns remain
regarding long-term outcomes and the possibility for reduced no-
dal harvest with a laparoscopic approach [15,16] [I, A]. In addition,
operative morbidity is greater particularly in total gastrectomy and
there remains a lack of consensus on the preferred approach to the
technique of anastomosis following a laparoscopic total gastrec-
tomy. Trials are currently ongoing in Japan (JCOG-0912), Korea
(KLASS and KLASS-02) and China to compare open versus laparo-
scopic surgery in early gastric cancer, and these should provide
further evidence regarding the role of laparoscopic surgery.Perioperative chemotherapy
The UK MRC MAGIC trial was the ﬁrst trial to evaluate the role
of perioperative chemotherapy with six cycles of ECF [epirubicin
50 mg/m2 D1, cisplatin 60 mg/m2 D1 and 5-ﬂuorouracil (5-FU)
200 mg/m2/day D1–21 Q21] compared with surgery alone in pa-
tients with resectable stage II and III gastric cancers [17].The re-
sults demonstrated that chemotherapy improved the 5-year
survival rate from 23% to 36%, with manageable toxic effects. A
subsequent FNCLCC (Féderation Nationale des Centres de Lutte Con-
tre le Cancer) and FFCD (Fédération Francophone de la Cancérologie
Digestive) trial has reported similar results with the use of a 28-
day regimen of perioperative cisplatin (100 mg/m2 D1) and 5-FU
(800 mg/m2/day D1–5) [18]. Perioperative chemotherapy has
therefore been widely adopted as the standard of care throughout
most of the UK and Europe [I, A]. Since capecitabine avoids the
need for an indwelling central venous access device, and is non-
inferior to 5-FU in the advanced disease setting [19], many centres
use ECX (epirubicin, cisplatin, capecitabine) peri-operatively in
preference to ECF [IV, C]. Other platinum/ﬂuoropyrimidine dou-
blets may be considered in patients with speciﬁc drug
contraindications.Adjuvant chemoradiotherapy
For patients who undergo surgery for >stage IB oesophago-gas-
tric cancer without administration of preoperative chemotherapy,
the treatment options include either chemoradiotherapy or che-
motherapy delivered in the adjuvant setting (see below). Evidence
is currently lacking to inform the choice between these two treat-
ment modalities in the adjuvant setting. Further data on these op-
tions are awaited from the ongoing randomised, phase III CRITICS
trial in which patients receive 3 cycles of pre-operative chemother-
apy followed by surgery and are then randomised between
adjuvant chemotherapy and chemoradiotherapy.
The North American Intergroup-0116 trial demonstrated that
adjuvant therapy with ﬁve cycles of 5-FU/leucovorin (Q28) plus
concomitant radiotherapy (45 Gy in 25 fractions over 5 weeks)
during cycles 2 and 3 resulted in improved OS at 5 years compared
with surgery alone. After 10 years of follow-up, this result remains
signiﬁcant with a hazard ratio for OS of 1.32 in favour of adjuvant
chemoradiotherapy [20] [I, A]. This treatment approach is consid-
ered standard therapy in the United States, though it has not
gained wide acceptance in Europe due to concerns about potential
late toxic effects and the quality of surgery within the trial.
Fifty-four percent of patients underwent less than a D1 lymphade-
nectomy, suggesting that post-operative chemoradiation may be
compensating for sub-optimal surgery [II, B]. This is supported by
retrospective data from the Dutch D1D2 trial, demonstrating that
chemoradiotherapy reduces local recurrence rates following D1
resection, but provides no beneﬁt in patients who have undergone
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Fig. 1. Algorithm for the management of gastric cancer.
192 Clinical practice guidelinesrandomised data suggest potential beneﬁts from postoperative
chemoradiation even after optimal D2 dissection [22–24] [I, B]
and this is the subject of ongoing randomised trials. A retrospective
comparison of the Dutch D1D2 trial has also conﬁrmed signiﬁcant
improvements in OS and local recurrence rates with use of chemo-
radiotherapy after a microscopically incomplete (R1) resection [21]
[IV, B].
In current postoperative chemoradiation regimens, radiother-
apy may be given to a total dose of 45 Gy in 25 fractions of
1.8 Gy, 5 fractions/week by 3D-conformal or intensity-modulated
radiation therapy techniques. The clinical target volume encom-
passes the gastric bed (with stomach remnant when present),
anastomoses and draining regional lymph nodes (for delineation
manual: www.critics.nl).
Adjuvant chemotherapy
A large, individual patient-level meta-analysis of adjuvant che-
motherapy in gastric cancer has conﬁrmed a 6% absolute beneﬁt
for 5-FU-based chemotherapy compared with surgery alone (HR
0.82, 95% CI 0.76–0.90; p < 0.001) in all subgroups tested [25] [I,
A]. However, historically a greater beneﬁt has been noted with this
approach in Asian studies compared with those in Western popu-
lations and uptake of this approach in Europe remains limited due
to a perceived lack of beneﬁt and routine use of perioperative che-
motherapy. In Asian populations, an OS beneﬁt following adjuvant
chemotherapy was conﬁrmed following D2 resection in the
ACTS-GC trial evaluating adjuvant S-1 [26] [I, A]. The CLASSIC trial
evaluated an adjuvant capecitabine–oxaliplatin doublet and has
reported signiﬁcantly improved overall and disease-free survival
[27] See Fig. 1.
Management of advanced/metastatic disease
Palliative chemotherapy and radiotherapy
Patients with stage IV disease should be considered for pallia-
tive chemotherapy, which improves survival compared with bestsupportive care alone [28] [I, A]. However, co-morbidities, organ
function and performance status must always be taken into con-
sideration [II, B]. Although resection of the primary tumour is not
generally recommended in the palliative setting, a small number
of advanced disease patients may be deemed to be operable fol-
lowing a good response to systemic therapy. Response to systemic
treatments should normally be assessed with interval CT imaging
of chest, abdomen and pelvis. Alternative imaging techniques
may be used if required to monitor known sites of disease (e.g.,
magnetic resonance imaging for bone lesions).
Combination regimens based upon a platinum–ﬂuoropyrimi-
dine doublet are generally used, and there remains controversy
regarding the need for triplet regimens. However, a meta-analysis
has demonstrated signiﬁcant beneﬁt from adding an anthracycline
to a platinum and ﬂuoropyrimidine doublet [28] [I, A]. The UK
REAL-2 trial demonstrated non-inferiority between ECF, ECX, EOF
(epirubicin, oxaliplatin, 5-FU) and EOX (epirubicin, oxaliplatin,
capecitabine) [19]. The EOX regimen was associated with numeri-
cally longer median OS (11.2 versus 9.9 months, HR 0.80, 95% CI,
0.66–0.97; p = 0.02) than ECF without the need for an indwelling
catheter and with reduced rates of thrombo-embolism [29]. Addi-
tionally, a meta-analysis has demonstrated that capecitabine is
associated with improved OS compared to infused 5-FU within
doublet and triplet regimes [30] [I, A].
Alternative ﬁrst-line chemotherapy options include taxane-
based regimens or irinotecan plus 5-FU [31]. The addition of
3-weekly docetaxel to 5-FU/cisplatin (DCF) is associated with in-
creased activity, but also adds toxic effects including increased
rates of febrile neutropaenia [32] [I, C]. Modiﬁed DCF regimens
therefore continue to be explored in an attempt to maintain activ-
ity whilst mitigating against excessive toxic effects.
In patients of adequate performance status, second-line chemo-
therapy is associated with proven improvements in OS and quality
of life compared with best supportive care, with treatment options
including irinotecan, docetaxel or paclitaxel [33–37] [I, A]. A ran-
domised phase III trial directly comparing weekly paclitaxel with
irinotecan has demonstrated similar efﬁcacy for both the regimens,
Table 4
Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America-United States Public Health Service Grading Systema).
Levels of evidence
I Evidence from at least one large randomised, controlled trial of good methodological quality (low potential for bias) or meta-analyses of well-conducted
randomised trials without heterogeneity
II Small randomised trials or large randomised trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials with
demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports, experts opinions
Grades of recommendation
A Strong evidence for efﬁcacy with a substantial clinical beneﬁt, strongly recommended
B Strong or moderate evidence for efﬁcacy but with a limited clinical beneﬁt, generally recommended
C Insufﬁcient evidence for efﬁcacy or beneﬁt does not outweigh the risk or the disadvantages (adverse events, costs, ...), optional
D Moderate evidence against efﬁcacy or for adverse outcome, generally not recommended
E Strong evidence against efﬁcacy or for adverse outcome, never recommended
a Dykewicz CA. Summary of the guidelines for preventing opportunistic infections amongst hematopoietic stem cell transplant recipients. Clin Infect Dis 2001;33:139–144.
By permission of the Infectious Diseases Society of America.
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A]. Additionally, consideration should always be given to inclusion
in any appropriate clinical trials [V, B]. Alternatively, in patients
with disease progression >3 months following ﬁrst-line chemo-
therapy, it may be appropriate to consider a re-challenge with
the same drug combination [IV, C].
In patients with symptomatic locally advanced or recurrent dis-
ease, hypo-fractionated radiotherapy is an effective and well-toler-
ated treatment modality which may palliate bleeding, obstructive
symptoms or pain [38] [III, B]. See Fig. 1.Personalised medicine
As in other solid organ tumours, the biological abnormalities
underpinning the development and progression of gastric cancer
are being increasingly elucidated through ongoing international
research. These tumours are now known to be highly molecularly
diverse and may be driven by a number of different genetic and
epigenetic abnormalities. Perhaps most notably, gastric cancers
are frequently found to harbour copy number alterations in key
oncogenes and tumour suppressor genes [39]. These ﬁndings have
potentially important therapeutic implications as oncologists at-
tempt to target the key pathways driving the tumour in each indi-
vidual patient.
In HER-2 positive gastric cancer (10–15% of cases), the phase III
ToGA trial demonstrated clinically and statistically signiﬁcant
improvements in response rate, progression-free survival (PFS)
and OS with the addition of trastuzumab to a cisplatin–ﬂuoropyr-
imidine doublet (median OS 13.8 versus 11.1 months, HR 0.74, 95%
CI, 0.60–0.91; p = 0.0048) [40]. The beneﬁts of trastuzumab were
even more marked in the traditionally deﬁned HER-2 positive sub-
group with IHC 2+/FISH-positive tumours, or IHC 3+ tumours. In
these patients the median OS was improved from 11.8 to
16.0 months (HR 0.65). Following the ToGA trial results, trast-
uzumab was licensed in Europe for use in HER-2 positive disease
(IHC3+ or 2+/FISH-positive) in combination with capecitabine or
5-ﬂuorouracil and cisplatin. This regimen now represents the stan-
dard of care for these patients [I, A].
The AVAGAST trial evaluating bevacizumab in combination
with ﬁrst-line chemotherapy failed to demonstrate any improve-
ment in OS, though both PFS and response rate were signiﬁcantly
improved [41] [I, C]. A second anti-angiogenic agent, ramucirumab,
has recently been conﬁrmed to have single-agent activity in the
second-line setting with a modest 1.4 month improvement in OS
compared to best supportive care [42] [I, B]. Neither agent is cur-
rently in routine clinical use.Anti-EGFR therapies have failed to improve outcomes with re-
cently reported negative phase III results when cetuximab [43] or
panitumumab [44] was added to ﬁrst-line chemotherapy, and a
negative phase III trial of single-agent geﬁtinib compared to best
supportive care in the second-line [45] [I, D].
Other molecular targets which are currently showing promise
in the advanced disease setting include:
 Overexpression or ampliﬁcation of the MET receptor – MET
targeted therapies are currently entering phase III trials in
this population.
 Ampliﬁcation of FGFR – anti-FGFR therapy is currently
undergoing evaluation.
Follow-up and long-term implications
 In the settingofoperablegastric cancer, the complexityof treat-
ment frequently induces symptoms which adversely affect
health-related quality of life. A regular follow-up may allow
investigation and treatment of symptoms, psychological sup-
port and early detection of recurrence, though there is no evi-
dence that it improves survival outcomes [46–48] [III, B].
 New strategies for patient follow-up are currently undergo-
ing evaluation, including patient-led self-referral and ser-
vices led by clinical nurse specialists.
 In the advanced disease setting, identiﬁcation of patients for
second-line chemotherapy and clinical trials requires regular
follow-up to detect symptoms of disease progression prior to
signiﬁcant clinical deterioration [IV, B].
 If relapse/disease progression is suspected then a clinical his-
tory, physical examination and directed blood tests should
be carried out. Radiological investigations should be carried
out in patients who are candidates for further chemo- or
radiotherapy [IV, B].
 The aggressive nature of gastric cancer, and historically poor
outcomes even in the setting of operable disease, mean that
the concept of survivorship is only now beginning to evolve.
Long-term implications, late effects of therapy, and psycho-
social implications of treatment are poorly studied to date.
Note
Levels of evidence and grades of recommendation have been
applied using the system shown in Table 4. Statements without
grading were considered justiﬁed standard clinical practice by
the experts and the ESMO faculty.
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